- Dr. Ron Najafi Highlights Aganocide Anti-Infective Platform - - Increasing Bacterial Resistance Requires New Treatment Paradigm -
EMERYVILLE, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that Dr. Ron Najafi, NovaBay's Chairman and Chief Executive Officer, was featured on the RedChip Money Report episode that aired on Fox Business on March 16, 2013. Dr. Najafi provided an overview of the Company's anti-infective programs and highlighted the Company's three Phase 2 trials currently underway, studying the Company's lead Aganocide auriclosene in dermatology, ophthalmology, and urology.
In addition, Dr. Najafi recently published a comprehensive discussion regarding the growing crisis of antibiotic resistance, addressing the history of bacteria and the rise of resistance. To access Dr. Najafi's CEO blog, as well as more information about NovaBay's technology, non-antibiotics that mimic the body's own defense systems, visit the Company's website, www.novabay.com .The RedChip Money Report segment from Fox Business is also available at the Company's website, in the Media section. About NovaBay Pharmaceuticals, Inc. Going Beyond Antibiotics NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides® and NeutroPhase® Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas. Aganocide ® Compounds NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, topical antimicrobials with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides are not subject to bacterial or fungal resistance, which has been demonstrated in in-vitro and in-vivo studies. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas: